{"id":830272,"date":"2025-03-26T16:49:05","date_gmt":"2025-03-26T20:49:05","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/edgewise-therapeutics-to-host-webcast-event-to-discuss-top-line-results-from-phase-2-cirrus-hcm-28-day-trial-of-edg-7500-in-hypertrophic-cardiomyopathy-hcm-on-wednesday-april-2-at-830-am-eastern-t\/"},"modified":"2025-03-26T16:49:05","modified_gmt":"2025-03-26T20:49:05","slug":"edgewise-therapeutics-to-host-webcast-event-to-discuss-top-line-results-from-phase-2-cirrus-hcm-28-day-trial-of-edg-7500-in-hypertrophic-cardiomyopathy-hcm-on-wednesday-april-2-at-830-am-eastern-t","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/edgewise-therapeutics-to-host-webcast-event-to-discuss-top-line-results-from-phase-2-cirrus-hcm-28-day-trial-of-edg-7500-in-hypertrophic-cardiomyopathy-hcm-on-wednesday-april-2-at-830-am-eastern-t\/","title":{"rendered":"Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Results from Phase 2 CIRRUS-HCM 28-Day Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) on Wednesday, April 2 at 8:30 am Eastern Time"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n
\n BOULDER, Colo.<\/span>
\n <\/span>, March 26, 2025<\/span><\/span> \/PRNewswire\/ — Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that members of the management team will hold a live webcast to discuss top-line data of EDG-7500 from the Phase 2 CIRRUS-HCM\u00a028-day trial in patients with obstructive or nonobstructive HCM on Wednesday, April 2, 2025<\/span>, at 8:30 am ET<\/span>.\u00a0 The team is excited to be joined by two of the Company’s CIRRUS-HCM investigators, who are world leaders in the care of patients with HCM.\u00a0 An accompanying slide presentation will also be available. To register for the live webcast and replay, please visit the Edgewise\u00a0events page<\/a><\/u>.<\/p>\n

\n

\n
\n \"Edgewise
\n <\/a>\n <\/p>\n<\/p><\/div>\n

\n About EDG-7500<\/b>\n <\/p>\n

EDG-7500 is a novel oral, selective, cardiac sarcomere modulator, specifically designed to slow early contraction velocity and address impaired cardiac relaxation associated with hypertrophic cardiomyopathy (HCM) and other diseases of diastolic dysfunction. To learn more about CIRRUS-HCM, visit clinicaltrials.gov, NCT06347159 (Phase 2)<\/a><\/u>.\u00a0<\/p>\n

\n About Edgewise Therapeutics<\/b>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/p>\n

Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company’s deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, currently in Phase 2 clinical development. The entire team at Edgewise is dedicated to our mission:\u00a0 changing the lives of patients and families affected by serious muscle diseases. To learn more, go to: www.edgewisetx.com<\/a><\/u>\u00a0or follow us on LinkedIn<\/a><\/u>, X<\/a><\/u>,\u00a0Facebook<\/a><\/u> and Instagram<\/a>.<\/u><\/p>\n

This press release contains hyperlinks to information that is not deemed to be incorporated by reference into this press release.<\/p>\n

\n Edgewise Contacts<\/b>
\n
\n Investors:<\/b>
\n
\n Michael Carruthers<\/span>, Chief Financial Officer
ir@edgewisetx.com<\/a>\u00a0<\/p>\n

\n Media:<\/b>
\n
\n Maureen Franco<\/span>, VP Corporate Communications
media@edgewisetx.com<\/a><\/p>\n

\n \"Cision\" View original content to download multimedia:https:\/\/www.prnewswire.com\/news-releases\/edgewise-therapeutics-to-host-webcast-event-to-discuss-top-line-results-from-phase-2-cirrus-hcm-28-day-trial-of-edg-7500-in-hypertrophic-cardiomyopathy-hcm-on-wednesday-april-2-at-830-am-eastern-time-302412513.html<\/a><\/p>\n

SOURCE Edgewise Therapeutics<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire BOULDER, Colo. , March 26, 2025 \/PRNewswire\/ — Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that members of the management team will hold a live webcast to discuss top-line data of EDG-7500 from the Phase 2 CIRRUS-HCM\u00a028-day trial in patients with obstructive or nonobstructive HCM on Wednesday, April 2, 2025, at 8:30 am ET.\u00a0 The team is excited to be joined by two of the Company’s CIRRUS-HCM investigators, who are world leaders in the care of patients with HCM.\u00a0 An accompanying slide presentation will also be available. To register for the live webcast and replay, please visit the Edgewise\u00a0events page. About EDG-7500 EDG-7500 is a novel oral, selective, cardiac sarcomere modulator, specifically … <\/p>\n

Continue reading “Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Results from Phase 2 CIRRUS-HCM 28-Day Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) on Wednesday, April 2 at 8:30 am Eastern Time”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-830272","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nEdgewise Therapeutics to Host Webcast Event to Discuss Top-Line Results from Phase 2 CIRRUS-HCM 28-Day Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) on Wednesday, April 2 at 8:30 am Eastern Time - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/edgewise-therapeutics-to-host-webcast-event-to-discuss-top-line-results-from-phase-2-cirrus-hcm-28-day-trial-of-edg-7500-in-hypertrophic-cardiomyopathy-hcm-on-wednesday-april-2-at-830-am-eastern-t\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Results from Phase 2 CIRRUS-HCM 28-Day Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) on Wednesday, April 2 at 8:30 am Eastern Time - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire BOULDER, Colo. , March 26, 2025 \/PRNewswire\/ — Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that members of the management team will hold a live webcast to discuss top-line data of EDG-7500 from the Phase 2 CIRRUS-HCM\u00a028-day trial in patients with obstructive or nonobstructive HCM on Wednesday, April 2, 2025, at 8:30 am ET.\u00a0 The team is excited to be joined by two of the Company’s CIRRUS-HCM investigators, who are world leaders in the care of patients with HCM.\u00a0 An accompanying slide presentation will also be available. To register for the live webcast and replay, please visit the Edgewise\u00a0events page. About EDG-7500 EDG-7500 is a novel oral, selective, cardiac sarcomere modulator, specifically … Continue reading "Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Results from Phase 2 CIRRUS-HCM 28-Day Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) on Wednesday, April 2 at 8:30 am Eastern Time"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/edgewise-therapeutics-to-host-webcast-event-to-discuss-top-line-results-from-phase-2-cirrus-hcm-28-day-trial-of-edg-7500-in-hypertrophic-cardiomyopathy-hcm-on-wednesday-april-2-at-830-am-eastern-t\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-26T20:49:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/2646316\/Edgewise_Therapeutics_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/edgewise-therapeutics-to-host-webcast-event-to-discuss-top-line-results-from-phase-2-cirrus-hcm-28-day-trial-of-edg-7500-in-hypertrophic-cardiomyopathy-hcm-on-wednesday-april-2-at-830-am-eastern-t\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/edgewise-therapeutics-to-host-webcast-event-to-discuss-top-line-results-from-phase-2-cirrus-hcm-28-day-trial-of-edg-7500-in-hypertrophic-cardiomyopathy-hcm-on-wednesday-april-2-at-830-am-eastern-t\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Results from Phase 2 CIRRUS-HCM 28-Day Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) on Wednesday, April 2 at 8:30 am Eastern Time\",\"datePublished\":\"2025-03-26T20:49:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/edgewise-therapeutics-to-host-webcast-event-to-discuss-top-line-results-from-phase-2-cirrus-hcm-28-day-trial-of-edg-7500-in-hypertrophic-cardiomyopathy-hcm-on-wednesday-april-2-at-830-am-eastern-t\\\/\"},\"wordCount\":354,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/edgewise-therapeutics-to-host-webcast-event-to-discuss-top-line-results-from-phase-2-cirrus-hcm-28-day-trial-of-edg-7500-in-hypertrophic-cardiomyopathy-hcm-on-wednesday-april-2-at-830-am-eastern-t\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2646316\\\/Edgewise_Therapeutics_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/edgewise-therapeutics-to-host-webcast-event-to-discuss-top-line-results-from-phase-2-cirrus-hcm-28-day-trial-of-edg-7500-in-hypertrophic-cardiomyopathy-hcm-on-wednesday-april-2-at-830-am-eastern-t\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/edgewise-therapeutics-to-host-webcast-event-to-discuss-top-line-results-from-phase-2-cirrus-hcm-28-day-trial-of-edg-7500-in-hypertrophic-cardiomyopathy-hcm-on-wednesday-april-2-at-830-am-eastern-t\\\/\",\"name\":\"Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Results from Phase 2 CIRRUS-HCM 28-Day Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) on Wednesday, April 2 at 8:30 am Eastern Time - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/edgewise-therapeutics-to-host-webcast-event-to-discuss-top-line-results-from-phase-2-cirrus-hcm-28-day-trial-of-edg-7500-in-hypertrophic-cardiomyopathy-hcm-on-wednesday-april-2-at-830-am-eastern-t\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/edgewise-therapeutics-to-host-webcast-event-to-discuss-top-line-results-from-phase-2-cirrus-hcm-28-day-trial-of-edg-7500-in-hypertrophic-cardiomyopathy-hcm-on-wednesday-april-2-at-830-am-eastern-t\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2646316\\\/Edgewise_Therapeutics_Logo.jpg\",\"datePublished\":\"2025-03-26T20:49:05+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/edgewise-therapeutics-to-host-webcast-event-to-discuss-top-line-results-from-phase-2-cirrus-hcm-28-day-trial-of-edg-7500-in-hypertrophic-cardiomyopathy-hcm-on-wednesday-april-2-at-830-am-eastern-t\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/edgewise-therapeutics-to-host-webcast-event-to-discuss-top-line-results-from-phase-2-cirrus-hcm-28-day-trial-of-edg-7500-in-hypertrophic-cardiomyopathy-hcm-on-wednesday-april-2-at-830-am-eastern-t\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/edgewise-therapeutics-to-host-webcast-event-to-discuss-top-line-results-from-phase-2-cirrus-hcm-28-day-trial-of-edg-7500-in-hypertrophic-cardiomyopathy-hcm-on-wednesday-april-2-at-830-am-eastern-t\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2646316\\\/Edgewise_Therapeutics_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2646316\\\/Edgewise_Therapeutics_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/edgewise-therapeutics-to-host-webcast-event-to-discuss-top-line-results-from-phase-2-cirrus-hcm-28-day-trial-of-edg-7500-in-hypertrophic-cardiomyopathy-hcm-on-wednesday-april-2-at-830-am-eastern-t\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Results from Phase 2 CIRRUS-HCM 28-Day Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) on Wednesday, April 2 at 8:30 am Eastern Time\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Results from Phase 2 CIRRUS-HCM 28-Day Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) on Wednesday, April 2 at 8:30 am Eastern Time - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/edgewise-therapeutics-to-host-webcast-event-to-discuss-top-line-results-from-phase-2-cirrus-hcm-28-day-trial-of-edg-7500-in-hypertrophic-cardiomyopathy-hcm-on-wednesday-april-2-at-830-am-eastern-t\/","og_locale":"en_US","og_type":"article","og_title":"Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Results from Phase 2 CIRRUS-HCM 28-Day Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) on Wednesday, April 2 at 8:30 am Eastern Time - Market Newsdesk","og_description":"PR Newswire BOULDER, Colo. , March 26, 2025 \/PRNewswire\/ — Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that members of the management team will hold a live webcast to discuss top-line data of EDG-7500 from the Phase 2 CIRRUS-HCM\u00a028-day trial in patients with obstructive or nonobstructive HCM on Wednesday, April 2, 2025, at 8:30 am ET.\u00a0 The team is excited to be joined by two of the Company’s CIRRUS-HCM investigators, who are world leaders in the care of patients with HCM.\u00a0 An accompanying slide presentation will also be available. To register for the live webcast and replay, please visit the Edgewise\u00a0events page. About EDG-7500 EDG-7500 is a novel oral, selective, cardiac sarcomere modulator, specifically … Continue reading \"Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Results from Phase 2 CIRRUS-HCM 28-Day Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) on Wednesday, April 2 at 8:30 am Eastern Time\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/edgewise-therapeutics-to-host-webcast-event-to-discuss-top-line-results-from-phase-2-cirrus-hcm-28-day-trial-of-edg-7500-in-hypertrophic-cardiomyopathy-hcm-on-wednesday-april-2-at-830-am-eastern-t\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-26T20:49:05+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/2646316\/Edgewise_Therapeutics_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/edgewise-therapeutics-to-host-webcast-event-to-discuss-top-line-results-from-phase-2-cirrus-hcm-28-day-trial-of-edg-7500-in-hypertrophic-cardiomyopathy-hcm-on-wednesday-april-2-at-830-am-eastern-t\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/edgewise-therapeutics-to-host-webcast-event-to-discuss-top-line-results-from-phase-2-cirrus-hcm-28-day-trial-of-edg-7500-in-hypertrophic-cardiomyopathy-hcm-on-wednesday-april-2-at-830-am-eastern-t\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Results from Phase 2 CIRRUS-HCM 28-Day Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) on Wednesday, April 2 at 8:30 am Eastern Time","datePublished":"2025-03-26T20:49:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/edgewise-therapeutics-to-host-webcast-event-to-discuss-top-line-results-from-phase-2-cirrus-hcm-28-day-trial-of-edg-7500-in-hypertrophic-cardiomyopathy-hcm-on-wednesday-april-2-at-830-am-eastern-t\/"},"wordCount":354,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/edgewise-therapeutics-to-host-webcast-event-to-discuss-top-line-results-from-phase-2-cirrus-hcm-28-day-trial-of-edg-7500-in-hypertrophic-cardiomyopathy-hcm-on-wednesday-april-2-at-830-am-eastern-t\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2646316\/Edgewise_Therapeutics_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/edgewise-therapeutics-to-host-webcast-event-to-discuss-top-line-results-from-phase-2-cirrus-hcm-28-day-trial-of-edg-7500-in-hypertrophic-cardiomyopathy-hcm-on-wednesday-april-2-at-830-am-eastern-t\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/edgewise-therapeutics-to-host-webcast-event-to-discuss-top-line-results-from-phase-2-cirrus-hcm-28-day-trial-of-edg-7500-in-hypertrophic-cardiomyopathy-hcm-on-wednesday-april-2-at-830-am-eastern-t\/","name":"Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Results from Phase 2 CIRRUS-HCM 28-Day Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) on Wednesday, April 2 at 8:30 am Eastern Time - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/edgewise-therapeutics-to-host-webcast-event-to-discuss-top-line-results-from-phase-2-cirrus-hcm-28-day-trial-of-edg-7500-in-hypertrophic-cardiomyopathy-hcm-on-wednesday-april-2-at-830-am-eastern-t\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/edgewise-therapeutics-to-host-webcast-event-to-discuss-top-line-results-from-phase-2-cirrus-hcm-28-day-trial-of-edg-7500-in-hypertrophic-cardiomyopathy-hcm-on-wednesday-april-2-at-830-am-eastern-t\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2646316\/Edgewise_Therapeutics_Logo.jpg","datePublished":"2025-03-26T20:49:05+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/edgewise-therapeutics-to-host-webcast-event-to-discuss-top-line-results-from-phase-2-cirrus-hcm-28-day-trial-of-edg-7500-in-hypertrophic-cardiomyopathy-hcm-on-wednesday-april-2-at-830-am-eastern-t\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/edgewise-therapeutics-to-host-webcast-event-to-discuss-top-line-results-from-phase-2-cirrus-hcm-28-day-trial-of-edg-7500-in-hypertrophic-cardiomyopathy-hcm-on-wednesday-april-2-at-830-am-eastern-t\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/edgewise-therapeutics-to-host-webcast-event-to-discuss-top-line-results-from-phase-2-cirrus-hcm-28-day-trial-of-edg-7500-in-hypertrophic-cardiomyopathy-hcm-on-wednesday-april-2-at-830-am-eastern-t\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/2646316\/Edgewise_Therapeutics_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/2646316\/Edgewise_Therapeutics_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/edgewise-therapeutics-to-host-webcast-event-to-discuss-top-line-results-from-phase-2-cirrus-hcm-28-day-trial-of-edg-7500-in-hypertrophic-cardiomyopathy-hcm-on-wednesday-april-2-at-830-am-eastern-t\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Results from Phase 2 CIRRUS-HCM 28-Day Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) on Wednesday, April 2 at 8:30 am Eastern Time"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/830272","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=830272"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/830272\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=830272"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=830272"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=830272"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}